MA-DESKTOP-METAL
18.6.2024 14:31:33 CEST | Business Wire | Press release
Desktop Metal (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced that platinum is now a customer-qualified material on the Production System™ P-1 with a specialty powder developed by Legor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618795152/en/
Platinum jewelry designs 3D printed by Legor on a Desktop Metal Production System P-1 are slated to be part of a multi-material, multi-customer jewelry display featured by Desktop Metal at Rapid + TCT, North America’s largest additive manufacturing and industrial 3D printing event, to be held June 25-27 in Los Angeles. The Legor parts to be shown include including a classic wedding band, a gemstone ring, and an intricate leaf earring. (Photo: Business Wire)
Legor is a full-service jewelry manufacturing solutions provider, and the company’s Powmet line of certified ultra-pure metal powders is produced for use with both laser and binder jet 3D printing systems.
“The qualification of Legor’s Powmet platinum on the Production System P-1 is another major milestone for binder jet 3D printing for the jewelry, watchmaking, and luxury goods industry,” said Ric Fulop, Founder and CEO of Desktop Metal. “Platinum is known to be a challenging-to-process material in the jewelry industry because of its high hardness and melting point. Our binder jet 3D printing process simplifies platinum production and enables all-new, once-impossible designs.”
”Legor is currently experiencing significant market interest in 3D printing technology, specifically in binder jet technology,” added Fabio Di Falco, Marketing and Customer Support Manager at Legor. “This has led us to address a variety of requests, ranging from prototyping to small batch production, as well as larger production runs. Thanks to binder jet 3D printing technology, designers can finally imagine and create objects that are currently unproducible with other technologies, thus expanding the boundaries of creativity to shape the future. At Legor, we are committed to becoming catalysts for innovation and promoting technology we are convinced represents a crucial turning point for our industry.”
Platinum jewelry designs 3D printed by Legor — including a classic wedding band, a gemstone ring, and an intricate leaf earring — are slated to be part of a multi-material, multi-customer jewelry display featured by Desktop Metal at Rapid + TCT, North America’s largest additive manufacturing and industrial 3D printing event, to be held June 25-27 in Los Angeles.
Binder Jet 3D Printing for Jewelry and Watchmaking
In 2023, Legor invested in a Desktop Metal Production System P-1, a high-speed, 1-liter binder jet 3D printing system featuring Single Pass Jetting (SPJ) technology. The experienced jewelry manufacturer notes that binder jet 3D printing technology offers several benefits over traditional manufacturing methods and other forms of 3D printing for jewelry production including:
- Rapid production of jewelry samples without molds or printing supports
- All-new design freedom for fast, affordable production of hollow, interlinked, intricate, and mass customized designs
- Elimination of processing steps associated with jewelry designs, such as welding
- Simplified production of materials that are difficult to work with, such as platinum, which often requires special tools
- Low waste production that is eco-friendly and uses only the necessary amount of metal needed to create the design
Legor’s Di Falco noted that sustainability is an important feature of binder jet 3D printing technology for the jewelry industry and Legor specifically.
“Binder jet 3D printing technology represents a significant step toward more sustainable production,” he noted, “enabling energy efficiency, and reducing the amount of material used. Indeed, binder jetting uses exactly the amount of material necessary to create an object, drastically reducing waste. The metal powder not used in the process can be reused, reducing the need for new raw materials and the risks associated with metal extraction. At Legor, we advocate for 3D printing as a responsible production approach that also considers the planet and people.”
A video by Legor showing the benefits of binder jetting platinum jewelry can be viewed at https://legor.com/en/prodotto/platinum-3d-printing/.
For more information about binder jetting jewelry with DM technologies, visit TeamDM.com/jewelry.
About Desktop Metal
Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in these communications, including statements regarding Desktop Metal’s future results of operations and financial position, financial targets, business strategy, and plans and objectives for future operations, are forward-looking statements. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: risks associated with the integration of the business and operations of acquired businesses; Desktop Metals’ ability to realize the benefits from cost saving measures; supply and logistics disruptions, including shortages and delays. For more information about risks and uncertainties that may impact Desktop Metal’s business, financial condition, results of operations and prospects generally, please refer to Desktop Metal’s reports filed with the SEC, including without limitation the “Risk Factors” and/or other information included in the Form 10-Q filed with the SEC on August 3, 2023, and such other reports as Desktop Metal has filed or may file with the SEC from time to time. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618795152/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
